Drug Profile
Research programme: viral disease therapeutics - GlaxoSmithKline/Roche
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Santaris Pharma
- Developer Roche
- Class Antisense oligonucleotides
- Mechanism of Action Antisense RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Viral-infections in Denmark (Parenteral)
- 19 Dec 2007 Preclinical trials in Viral infections in Denmark (unspecified route)